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Conclusions: Preliminary results suggest that Phi29-based whole 
genome ampliﬁcation introduces structural biases that may be related to 
the composition of the underlying DNA sequence. Some of the repro-
ducible biases induced by Phi29-based WGA may be compensated for 
by amplifying both samples in pair-wise copy number comparisons.
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Background: Adenocarcinoma is the most frequent histological sub-
types of lung cancers and atypical adenomatous hyperplasia (AAH) is 
considered as a preneoplastic lesion of adenocarcinoma. According to a 
hypothesis of multistep carcinogenesis, lung adenocarcinoma develops 
AAH to invasive adenocarcinoma through bronchioloalveolar carci-
noma (BAC). Noguchi classiﬁed small peripheral lung adenocarcinoma 
measured 2 cm or less in the greatest diameter into 6 types. Among 
them, type A, B and C have BAC components. EGFR mutations are 
frequently detected in never smokers and adenocarcinomas, especially 
those with BAC features. We investigate EGFR mutations, EGFR gene 
copy number, and KRAS mutations in AAH and Noguchi’s type A-C 
and analyzed the association among histological subsets and genetic 
and clinicopathological factors to clarify the role of genetic alterations 
on carcinogenesis of adenocarcinoma with BAC component.
Methods: Sixty lesions measured 2cm or less in greatest dimension 
which were obtained from 48 patients by surgery were studied: 4 AAH, 
19 Noguchi’s type A, 15 type B and 22 type C. EGFR mutations were 
examined using a mutant-enriched PCR assay for exon 19 deletions and 
L858R exon 21 mutation, and KRAS mutations were examined using 
a PCR assay for codon 12 point mutations. EGFR copy number was 
detected by a ﬂuorescence in situ hybridization (FISH) assay. 
Results: One lesion of AAHs had EGFR mutations (25%), but there 
were no KRAS mutations and high EGFR copy number status in 
AAHs. EGFR alterations had a tendency to increase the positive 
alteration according to the advance of histological classiﬁcation, and 
high EGFR copy number status was signiﬁcant frequently detected in 
Noguchi’s type C than AAH-B group including AAH, Noguchi’s type 
A and B in univariate analysis (Type C versus AAH-B: 31.8% versus 
5.3%, P=0.0091). KRAS mutations were detected in 5 lesions (8.3%) 
among total 60 lesions without statistical correlation with other factors. 
Multivariate analysis revealed that Noguchi’s type C signiﬁcantly cor-
related with larger tumor size (OR=3.61, 95%CI: 1.12-11.6, P=0.031) 
and high EGFR copy number status (OR=5.94, 95%CI: 1.25-28.3, 
P=0.025) than AAH-B group. 
Conclusions: EGFR mutations occur in the AAH lesion and may inﬂu-
ence the carcinogenesis of lung adenocarcinoma. By contrast, increased 
EGFR copy number may be a late event of tumor development and 
play a role in the progression of lung adenocarcinoma. 
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Background: KRAS codon 12 mutations occur in about 30% of 
non-small cell lung cancer (NSCLC) tissue and are associated with 
adenocarcinoma histology, poor survival and resistance to erlotinib or 
geﬁtinib. In this study, we evaluated the reliability and clinical signiﬁ-
cance of plasma KRAS mutations in NSCLC patients. 
Patients and Methods: 180 Swiss patients with NSCLC were screened 
for KRAS mutations in plasma and matched peripheral blood mono-
nuclear cells (PBMC) using a combined restriction fragment-length 
polymorphism and polymerase chain reaction (RFLP-PCR) assay. Sur-
vival analysis was performed using the Kaplan-Meier method and the 
Cox multivariate model. KRAS mutations were validated in a second 
laboratory by DNA sequencing, using matched plasma, serum, PBMC 
and tumor tissue. 
Results: Baseline characteristics: 69% male, 69% smokers, 86% stage 
IIIB/IV and 44% adenocarcinoma. Median age at diagnosis was 61 
years and median survival was 12 months. Chemotherapy was given 
to 78% of the patients, 27% had surgical resection and 12% radia-
tion. Mutation screening revealed KRAS mutations in 16/180 (9%) 
plasma and 0/180 (0%) PBMC samples. Plasma KRAS mutations (P 
= 0.014), tumor stage (P < 0.001) and surgical resection (P < 0.001) 
were independent predictors of prognosis in the multivariate model. 
No signiﬁcant associations were found between plasma KRAS muta-
tions and baseline characteristics or response to chemotherapy. DNA 
sequencing conﬁrmed circulating KRAS mutations in 11/15 evaluable 
cases. KRAS codon 12 sequences matched between blood and tumors 
in 7/9 evaluable cases. 
Conclusions: Plasma KRAS mutations were associated with poor 
survival and concordant with tumor KRAS mutations. Further studies 
are warranted to test if plasma KRAS mutations predict resistance to 
erlotinib or geﬁtinib in NSCLC patients. 
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Background: An increased copy number for the epidermal growth 
factor receptor (EGFR) gene has been suggested to be a valid marker to 
predict response of EGFR inhibitors in the advanced stage of lung can-
cer. However, no clear evidence has been demonstrated as to whether 
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EGFR copy number per se can affect the clinical outcome of adenocar-
cinoma of the lung after surgical resection.
Methods: We analyzed 106 cases of primary pulmonary adenocarcino-
ma who underwent curative resection and whose parafﬁn blocks were 
available. We excluded patients who received preoperative chemother-
apy and who were presented with distant metastasis. The EGFR gene 
copy number was evaluated using ﬂuorescence in situ hybridization 
(FISH) and its prognostic implication was analyzed along with other 
clinical risk factors. 
Results: There were 43 males and 63 females and the mean age was 
59.4 (29-85) years. We detected a high EGFR gene copy number in 39 
cases (36.8%), among whom, 8 cases (7.5%) showed ampliﬁcation. 
The high EGFR gene copy was not associated with gender, smoking 
status, presence of bronchioloalveolar cell feature, or pathologic TNM 
stage. All patients were followed up at the clinic with mean follow 
up periods of 27.7 (2.9-69.6) months. The overall 5 year survival was 
54.6% and that of disease speciﬁc survival was 38.2%. The risk factors 
affecting the overall survival were male gender (p=0.0007), smoking 
history (p=0.0093), and advanced stage (≥IIA; p=0.0375) in univari-
able analysis. For disease speciﬁc survival, male gender (p=0.0333), 
absence of bronchioloalveolar feature (p=0.0223), advanced stage 
(p=0.0016), and ampliﬁcation of EGFR gene copy (p=0.0295) were 
risk factors in univariable analysis. In multivariable analysis, advanced 
stage (p=0.001) and EGFR gene ampliﬁcation (p=0.014) remained as 
signiﬁcant risk factors for poor disease speciﬁc survival.
Conclusions: We demonstrated that ampliﬁcation of the EGFR gene 
affected the clinical outcome of adenocarcinoma of the lung after surgi-
cal resection in terms of disease speciﬁc survival. This result provides 
an important message for the protocol design of future trials using 
EGFR inhibitor. As EGFR gene ampliﬁcation itself is a poor prognostic 
factor for disease recurrence, the EGFR gene copy number should be 
investigated and analyzed in the context of other clinical risk factors in 
such clinical trials. 
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Background: We evaluated the correspondence between EGFR 
mutations in NSCLC tissue and matched serum DNA and the value of 
EGFR mutations as a serological marker. 
Methods: 121 Spanish stage IV NSCLC p received customized ﬁrst- or 
second-line erlotinib monotherapy based on the presence of EGFR 
mutations in the tumor tissue. Serum genomic DNA was obtained from 
all p prior to erlotinib administration. EGFR exon 19 deletions were 
studied by length analysis of ﬂuorescently labeled PCR products and 
the exon 21 L858R mutation by a PCR Taqman assay. 
Results: The EGFR mutation status in the serum was consistent with 
that in the tumor tissue of 82/121 p (68%) and of 15/16 p (93.8%) with 
PS 2 had mutations. Overall, 64.3% of p had an exon 19 deletion and 
35.7% had L858R. 78% of mutations were found in females (P=0.01) 
and 77.6% in never-smokers (P=0.07). Response rate was 88% in 
p with mutations only in the tumor and 87% in p with mutations in 
tumor and serum. Complete responses were observed in 20% of p with 
mutations in tumor and serum vs 4% of p with mutations only in tumor 
(P=0.09). With a median follow-up of 6.8 months (m) (range, 1.2-17.6), 
time to progression (TTP) and median survival have not been reached. 
A trend to better outcome was seen in p without serum EGFR muta-
tions. TTP was longer for p with EGFR exon 19 deletions (not reached) 
than for p with L858R (7.7 m) (P=0.02). TTP for p with PS 2 with exon 
19 deletions was not reached, while it was 2.7 m for p with L858R 
(P=0.17). 
Conclusions: EGFR mutations in serum could be a non-invasive 
source of information on the genotype of the original tumor cells and 
could be a useful tool to predict p response to erlotinib, especially in p 
with poor PS.
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